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greement on the processes of health care that are necessary
o achieve health care quality goals is the foundation of
erformance measurement. In addition, standardization of
erformance measures themselves is essential to avoid con-
usion and undue burden among those whose performance
s being measured. Recent work on cardiovascular perfor-
ance measures establishes a new standard for how those
greements can be achieved and maintained among multiple
takeholders. The collaboration among the American Col-
ege of Cardiology (ACC), the American Heart Association
AHA), the Centers for Medicare and Medicaid Services
CMS), the Joint Commission on Accreditation of Health-
are Organizations (JCAHO), and the Agency for Health-
are Research and Quality (AHRQ) serves as a useful model
or how to reduce the burden of measure development,
ndorsement for public reporting, and implementation for
uality improvement and accountability.
See page 236
The collaboration started in 1993 when the ACC lent its
upport to an effort by CMS (then the Health Care
inancing Administration) to develop objective perfor-
ance measures based on the ACC/AHA Guideline on the
arly Management of Patients With Acute Myocardial
nfarction. Those measures were used to track inpatient
are, first at the state level (1) and then at the national level
2,3). The ACC and AHA also supported measure devel-
pment efforts by the JCAHO for its new requirement that
ospitals measure performance.
In 2000, as the ACC was developing the Guideline
pplied in Practice (GAP) program and the AHA was
eveloping Get With the Guidelines (GWTG), both orga-
izations recognized the need for a common set of measures
o accompany those quality improvement activities. The
teps for the development of these common measures have
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4).
With the initiation of public reporting in 2003, the CMS
nd JCAHO recognized that small discrepancies between
heir measures were creating major data abstraction burdens
or providers and distractions to quality improvement initi-
tives. As a result, the CMS and JCAHO joined together to
ublish consolidated measure specifications in 2004. When
he ACC and AHA published their draft joint measures a
ew months later, the four organizations recognized a need
nd an opportunity. The CMS and JCAHO reached out to
he ACC/AHA Task Force on Performance Measures to
stablish a dialogue about how the joint expertise of all four
rganizations could be leveraged to achieve national stan-
ardization of measurement for cardiovascular care.
The first tangible result of this collaboration was demon-
trated in 2004 in the response by all organizations to the
hanging use of angiotensin-converting enzyme inhibitors
ACEI) and angiotensin receptor blockers (ARB). We
ealized if all four organizations could agree on how to
odify this measure, then such agreement could be used as
model that would allow each organization to contribute its
trengths toward measurement development and would
ynchronize measure updates. The AHRQ supported these
fforts by bringing together the stakeholders for a one-day
ummit. The National Quality Forum (NQF) provided
dditional focus for this collaboration by highlighting the
eed to re-examine these NQF-endorsed measures. Within
onths of the first communication, the ACC, AHA, CMS,
nd JCAHO agreed that clinicians should be given credit
or the initiation of ACEI or ARB therapy at discharge for
cute myocardial infarction (AMI) and heart failure patients
5). The measurement specifications for both AMI and
eart failure were modified by all four organizations simul-
aneously. Resolving the ACEI/ARB issue provided an
pportunity to build trust among all parties. The clinical
xpertise of the ACC/AHA in evidence review and guide-
ine/measurement development was leveraged, while the
MS and JCAHO contributed their expertise in the devel-
pment, specification, and implementation of the measures.
he AHRQ and NQF served as important supporters
hrough their convening efforts.
The organizations collaborated again in 2005 when the
lopidogrel and Metoprolol in Myocardial Infarction
COMMIT/CCS-2) trial (6) raised questions about the
urrent acute beta-blocker measure for AMI. Within seven
eeks, the organizations jointly issued a practice advisory to
he health care community providing information on how
he data from the trial should be interpreted when imple-
enting the current beta-blocker measure (7).
The publication of the ACC/AHA Clinical Performance
easures for Adults With ST-Elevation and Non–ST-
levation Myocardial Infarction (STEMI/NSTEMI) (8)
ignals another step in the evolution of this national
ollaboration. All organizations have committed to impor-
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January 3, 2006:266–7 Editorial Commentant revisions to the current CMS/JCAHO AMI measure-
ent set based on recommendations within the ACC/AHA
TEMI/NSTEMI Clinical Performance Measures. These
uggestions will be implemented in two phases by the
MS/JCAHO.
The first phase will change the method of reporting for
he time-to-reperfusion measures (both thrombolytic and
ercutaneous coronary intervention [PCI]) from a report of
he mean time to a report of the median time. The median
ime more closely reflects the overall pattern of care and
etter portrays the central tendency of the data, because the
ean time is more heavily influenced by outlier cases. All
rganizations agreed that a change to a median time could
e accomplished without significant changes to data collec-
ion.
Additional changes during a second phase will refine the
easures specifications to determine the time to primary
CI (rather than all PCI procedures done during the first
ay), to take into account medical and patient-specific
easons for delay in primary PCI, and to modify the
hreshold time to PCI to 90 min in concordance with
uideline recommendations. A measure to assess the num-
er of patients who are eligible for reperfusion who receive
uch therapy also will be developed over the next year as all
rganizations work jointly to integrate such changes into
pecifications and data collection protocols.
All organizations want to assure the practicing commu-
ity that each organization is dedicated to a collaborative
rocess to achieve a single national measurement standard.
he ACC/AHA, CMS, JCAHO, and AHRQ plan to
ontinue their close communication to ensure that informa-
ion that may impact inpatient measures is discussed
romptly among all organizations and conveyed to the
ealth care community. In addition, these organizations will
ork with the Physician Consortium for Performance
mprovement to align inpatient and outpatient measures as
ecessary and appropriate. Lastly, measures that are ready
or national adoption will continue to be submitted to the
QF, confirming the commitment by all organizations
nvolved to provide various stakeholders with an opportu-
ity to review and endorse the measures as national stan-
ards.
Issues with performance measures will undoubtedly arise,hether from the results of new evidence or from feedbackfter the implementation of the measures by the health care
ommunity. To retain credibility with professionals, any
stablished system of performance measurement must be
imble enough to be able to respond appropriately to a
hanging evidence base. The physician community should
e assured that the ACC, AHA, CMS, JCAHO, and
HRQ are committed to continuing to help the measures
volve in a joint and collaborative way. That may be as much
f a contribution to health care quality improvement as the
easures themselves.
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